Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) also known as DR4, is encoded by the gene mapped to human chromosome 8p21-22. Recombinant human soluble TRAIL Receptor-1/DR4 is a 22.7kDa protein (216 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain. TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins. TRAIL-R1 contains a cytoplasmic "death domain," which can activate the cell’s apoptotic machinery. TRAIL Receptor-1/DR4 is activated by binding to either membrane anchored or soluble TRAIL/Apo2L.
Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) interacts with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and stimulate cell-death signaling pathway. Mutation of the sTRAIL-R1 gene is associated with the pathogenesis of non-Hodgkin′s lymphoma (NHL). In addition, variation of TRAIL-R1 also increases the risk of susceptibility to prostate cancer (PCa) in North Indian population.
MSGTGAAAAT PSKVWGSSAG RIEPRGGGRG ALPTSMGQHG PSARARAGRA PGPRPAREAS PRLRVHKTFK FVVVGVLLQV VPSSAATIKL HDQSIGTQQW EHSPLGELCP PGSHRSERPG ACNRCTEGVG YTNASQQLFA CLPCTACKSD EEERSPCTTT RNTACQCKPG TFRNDNSAEM CRKCSTGCPR GMVKVKDCTP WSDIECVHKE SGNGHN
Lyophilized with no additives.
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.